NASDAQ:ANCN

Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.76
$0.97
50-Day Range
$2.82
$59.00
52-Week Range
$0.51
$10.55
Volume
404,239 shs
Average Volume
3.15 million shs
Market Capitalization
$6.59 million
P/E Ratio
5.92
Dividend Yield
N/A
Price Target
N/A
ANCN stock logo

About Anchiano Therapeutics Stock (NASDAQ:ANCN)

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

ANCN Stock News Headlines

ITeos Therapeutics Inc Ordinary Shares
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
ENDV Endonovo Therapeutics, Inc.
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
See More Headlines
Receive ANCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/05/2019
Today
5/08/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANCN
CIK
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-27,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.01 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.59 million
Optionable
Not Optionable
Beta
0.93
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Ronald K. Knickerbocker (Age 55)
    Sr. VP of Clinical Devel. & Data Sciences
    Comp: $352k
  • Mr. Neil H. Cohen (Age 58)
    CEO & Director
  • Prof. Abraham Hochberg (Age 83)
    Co-Founder & Chief Scientific Officer
  • Mr. Andrew Fine (Age 51)
    Chief Financial Officer
  • Mr. Avraham Hampel M.B.A.
    Deputy CFO & Company Sec.
  • Mr. Or Dolev (Age 43)
    Controller

ANCN Stock Analysis - Frequently Asked Questions

How were Anchiano Therapeutics' earnings last quarter?

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) released its quarterly earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.12.

What other stocks do shareholders of Anchiano Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Abeona Therapeutics (ABEO), Achieve Life Sciences (ACHV), Acorda Therapeutics (ACOR), Acasti Pharma (ACST), Aduro Biotech (ADRO) and AnaptysBio (ANAB).

When did Anchiano Therapeutics IPO?

Anchiano Therapeutics (ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

This page (NASDAQ:ANCN) was last updated on 5/8/2024 by MarketBeat.com Staff

From Our Partners